EFFECTS OF OLMESARTAN ON LOCAL AND REGIONAL RIGIDITY OF ARTERIES IN ISCHEMIC HEART DISEASE
https://doi.org/10.15829/1728-8800-2014-3-41-46
Abstract
Aim. To evaluate 24-week treatment by olmesartan on rigidity of arteries in different vessel areas in patients with coronary heart disease (CHD) with 1–2 grade arterial hypertension (AH).
Material and methods. Into open-label, non-randomized trial 25 patients with CHD and 1–2 grade AH were included. During 24-week treatment period patients received olmesartan medoxomil 20–40 mg daily. Baseline and final parameters of arterial wall stiffness were measured using ultrasound method with echotracking. The thickness of intima-media (TIMC) was defined. To evaluate regional vessel stiffness the volume sphygmography method was used.
Results. Acorrding to the data of volume sphygmography terapy by olmesartan significantly decrease PWVao by 19,4%, R-PWV b L-PWV — by 11,9% and 11,6% (p<0,05). CAVI1 decreased by 9,3%; L–CAVI1 — by 13,7%, CAVI2 — на 14,9% (p<0,05). В-PWV did not change significantly. During 24-week medication treatment the regress of carotid atherosclerosis was marked: decrease of TIMC from 773,6±155,7 μm to 736,3±124,1 μm (p<0,05). The values loc P sys and loc P dia significantly decreased by 13,5% and 11% (p<0,05); rigidity index β by 19,1% (p<0,05). Also we marked the increase of transverse pliability by 3,3% (p<0,05) and decrease of loc PWV by 17% (p<0,05). The coefficient of transverse pliability, locAix and DOCA did not show significant changes.
Conclusion. Addition of olmesartan to the standard treatment of CHD and AH showed significant improvement of local and regional stiffness.
About the Authors
I. B. Matrosova
Medical Institution FSBEI HPE Penza State University. Penza, Russia
Russian Federation
Russian Federation
E. A. Melnikova
Medical Institution FSBEI HPE Penza State University. Penza, Russia
Russian Federation
Russian Federation
V. E. Oleynikov
Medical Institution FSBEI HPE Penza State University. Penza, Russia
Russian Federation
Russian Federation
References
1. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–52.
2. Touboul P-J, Hennerici MG, Meairs S, et al. Mannheim Carotid Intima-Media Thickness Consensus (2004–2006). Cerebrovasc Dis 2007; 23: 75–80.
3. Atherosclerosis and dislipidemiya. The magazine of national society on atherosclerosis studying 2011; 4: 5–7. Russian (Атеросклероз и дислипидемии. Журнал национального общества по изучению атеросклероза 2011; 4: 5–7).
4. Masson I, Boutouyrie P, Laurent S, et al. Characterization of arterial wall mechanical behavior and stresses from human. J Biomech 2008; 28: 2618–27.
5. Kukharchuk VV. Arterial hypertension, violations of a lipidic exchange and atherosclerosis in Chazov E.I, Chazova I. E. Guide to an arterial hypertension Moscow: Media Medica 2005; 289–99. Russian (Кухарчук В. В. Артериальная гипертония, нарушения липидного обмена и атеросклероз. В кн.: Чазов Е.И, Чазова И. Е. Руководство по артериальной гипертонии. М.: Медиа Медика 2005; 289–99).
6. Brunner H, Cockroft JD, Deanfield J, et al. Endothelian function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelian Factors of the European Society of Hypertension. J Hypertens 2005; 23 (2): 233–46.
7. Takai S, Jin D, Sakaguchi M, et al. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J Hypertens 2005; 23 (10): 1879–86.
8. Ferrario C. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Health Risk Manag 2009; 5: 301–14.
9. Hirohata A, Yamamoto K, Miyoshi T, et al. Impact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of olmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. JACC 2010; 55 (10): 976–982.
10. Van Popele NM, Grabbee DE, Bots ML, et al. Association between arterial stiffness and atherosclerosis: the Rotterdam study. Stroke 2001; 32: 454–60.
11. Tomiyama H, Koij Y, Yambe M, et al. Brachial-ankle pulse wave velocity is a simple and independent predictor of prognosis in patients with acute coronary syndrome. Circ J 2005; 69: 815–22.
12. Orlova YaA, Kuzmina AE, Masenko VP. Influence of rigidity of arteries on development of cardiovascular complications at coronary heart disease. Cardiology 2009; 12: 11–7. Russian (Орлова Я. А., Кузьмина А. Е., Масенко В. П. и др. Влияние жесткости артерий на развитие сердечно-сосудистых осложнений при ишемической болезни сердца. Кардиология 2009; 12: 11–7).
13. Horinaka S, Yabe A, Yagi H, et al. Cardio-ankle vascular index could reflect plaque burden in the coronary artery. Angiology 2011; 62 (5): 401–8.
14. Horinaka S, Yabe A, Yagi H, et al. Comparison of atherosclerotic indicators between cardio ankle vascular index and brachial ankle pulse wave velocity. Angiology 2009; 60 (4): 468–76.
15. Ong KT, Delerme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a metaanalysis of individual data in 294 patients. J Hypertens 2011; 29: 1034–42.
16. Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis 2012; 221: 18–33.
17. Savarese G, Costanco P, Cleland JGF, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. JACC 2013; 61 (2): 131–42.
Review
For citations:
Matrosova I.B., Melnikova E.A., Oleynikov V.E. EFFECTS OF OLMESARTAN ON LOCAL AND REGIONAL RIGIDITY OF ARTERIES IN ISCHEMIC HEART DISEASE. Cardiovascular Therapy and Prevention. 2014;13(3):41-46. (In Russ.) https://doi.org/10.15829/1728-8800-2014-3-41-46
Views:
754
Email this article 
